Send to a Friend Share

Dendreon (DNDN) May volatility elevated at 99 into data

November 10, 2009 8:05 AM EST
DNDN Hot Sheet
Overall Analyst Rating:
    NEUTRAL (= Flat)

Revenue Growth %: +191.8%
Dendreon (Nasdaq: DNDN) closed at $29.31. DNDN's provenge (a drug that prolongs the lives of advanced prostate-cancer patients) has a PDUFA this spring. DNDN December option implied is at 70, February is at 74, May is at 99; verses its six-month average of 75, according to Track Data. Paul Foster

You May Also Be Interested In


Related Categories

Options

Add Your Comment





Follow StreetInsider.com On Twitter